Fcγ receptor 3B polymorphism is associated with hypersensitivity reactions to adalimumab in Japanese patients with rheumatoid arthritis

Masako Tsukamoto, Hideto Kameda, Tatsuhiro Ohshige, Yuko Kaneko, Keiko Yoshimoto, Katsuya Suzuki, Tsutomu Takeuchi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: To examine the association between Fcγ receptor (FcγR) polymorphisms and the development of hypersensitivity reactions to adalimumab in patients with rheumatoid arthritis. Methods: Sixty-five patients receiving adalimumab were enrolled in the study. Genetic polymorphisms for FcγR3B were genotyped in FCGR3B NA1/2 alleles by real allelic discrimination assay. Clinical information and the occurrence of a hypersensitivity reaction to adalimumab were collected from the patients’ charts. Results: A hypersensitivity reaction was observed in 12% of the patients. Clinical information obtained from patients with a reaction and those without were the same. The FCGR3B NA1/NA1, NA1/NA2, and NA2/NA2 alleles were found in 75%, 13%, and 13% of the patients with hypersensitivity reaction, respectively, and in 28%, 42%, and 30% of those without a hypersensitivity reaction, respectively (p = 0.04). Multivariate logistic regression analysis identified only the NA1/NA1 as an independent relevant factor for a hypersensitivity reaction to adalimumab (OR 7.7, p = 0.01). Conclusions: The FCGR3B NA1/NA1 genotype is associated with hypersensitivity reactions to adalimumab.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalModern Rheumatology
DOIs
Publication statusAccepted/In press - 2016 Nov 16

Fingerprint

Fc Receptors
Rheumatoid Arthritis
Hypersensitivity
Alleles
Genetic Polymorphisms
Adalimumab
Logistic Models
Genotype
Regression Analysis

Keywords

  • Adalimumab
  • Injection site reaction
  • Polymorphism
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Fcγ receptor 3B polymorphism is associated with hypersensitivity reactions to adalimumab in Japanese patients with rheumatoid arthritis. / Tsukamoto, Masako; Kameda, Hideto; Ohshige, Tatsuhiro; Kaneko, Yuko; Yoshimoto, Keiko; Suzuki, Katsuya; Takeuchi, Tsutomu.

In: Modern Rheumatology, 16.11.2016, p. 1-4.

Research output: Contribution to journalArticle

@article{3937e97a10e146dfb753423909a2fb76,
title = "Fcγ receptor 3B polymorphism is associated with hypersensitivity reactions to adalimumab in Japanese patients with rheumatoid arthritis",
abstract = "Objectives: To examine the association between Fcγ receptor (FcγR) polymorphisms and the development of hypersensitivity reactions to adalimumab in patients with rheumatoid arthritis. Methods: Sixty-five patients receiving adalimumab were enrolled in the study. Genetic polymorphisms for FcγR3B were genotyped in FCGR3B NA1/2 alleles by real allelic discrimination assay. Clinical information and the occurrence of a hypersensitivity reaction to adalimumab were collected from the patients’ charts. Results: A hypersensitivity reaction was observed in 12{\%} of the patients. Clinical information obtained from patients with a reaction and those without were the same. The FCGR3B NA1/NA1, NA1/NA2, and NA2/NA2 alleles were found in 75{\%}, 13{\%}, and 13{\%} of the patients with hypersensitivity reaction, respectively, and in 28{\%}, 42{\%}, and 30{\%} of those without a hypersensitivity reaction, respectively (p = 0.04). Multivariate logistic regression analysis identified only the NA1/NA1 as an independent relevant factor for a hypersensitivity reaction to adalimumab (OR 7.7, p = 0.01). Conclusions: The FCGR3B NA1/NA1 genotype is associated with hypersensitivity reactions to adalimumab.",
keywords = "Adalimumab, Injection site reaction, Polymorphism, Rheumatoid arthritis",
author = "Masako Tsukamoto and Hideto Kameda and Tatsuhiro Ohshige and Yuko Kaneko and Keiko Yoshimoto and Katsuya Suzuki and Tsutomu Takeuchi",
year = "2016",
month = "11",
day = "16",
doi = "10.1080/14397595.2016.1254709",
language = "English",
pages = "1--4",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Fcγ receptor 3B polymorphism is associated with hypersensitivity reactions to adalimumab in Japanese patients with rheumatoid arthritis

AU - Tsukamoto, Masako

AU - Kameda, Hideto

AU - Ohshige, Tatsuhiro

AU - Kaneko, Yuko

AU - Yoshimoto, Keiko

AU - Suzuki, Katsuya

AU - Takeuchi, Tsutomu

PY - 2016/11/16

Y1 - 2016/11/16

N2 - Objectives: To examine the association between Fcγ receptor (FcγR) polymorphisms and the development of hypersensitivity reactions to adalimumab in patients with rheumatoid arthritis. Methods: Sixty-five patients receiving adalimumab were enrolled in the study. Genetic polymorphisms for FcγR3B were genotyped in FCGR3B NA1/2 alleles by real allelic discrimination assay. Clinical information and the occurrence of a hypersensitivity reaction to adalimumab were collected from the patients’ charts. Results: A hypersensitivity reaction was observed in 12% of the patients. Clinical information obtained from patients with a reaction and those without were the same. The FCGR3B NA1/NA1, NA1/NA2, and NA2/NA2 alleles were found in 75%, 13%, and 13% of the patients with hypersensitivity reaction, respectively, and in 28%, 42%, and 30% of those without a hypersensitivity reaction, respectively (p = 0.04). Multivariate logistic regression analysis identified only the NA1/NA1 as an independent relevant factor for a hypersensitivity reaction to adalimumab (OR 7.7, p = 0.01). Conclusions: The FCGR3B NA1/NA1 genotype is associated with hypersensitivity reactions to adalimumab.

AB - Objectives: To examine the association between Fcγ receptor (FcγR) polymorphisms and the development of hypersensitivity reactions to adalimumab in patients with rheumatoid arthritis. Methods: Sixty-five patients receiving adalimumab were enrolled in the study. Genetic polymorphisms for FcγR3B were genotyped in FCGR3B NA1/2 alleles by real allelic discrimination assay. Clinical information and the occurrence of a hypersensitivity reaction to adalimumab were collected from the patients’ charts. Results: A hypersensitivity reaction was observed in 12% of the patients. Clinical information obtained from patients with a reaction and those without were the same. The FCGR3B NA1/NA1, NA1/NA2, and NA2/NA2 alleles were found in 75%, 13%, and 13% of the patients with hypersensitivity reaction, respectively, and in 28%, 42%, and 30% of those without a hypersensitivity reaction, respectively (p = 0.04). Multivariate logistic regression analysis identified only the NA1/NA1 as an independent relevant factor for a hypersensitivity reaction to adalimumab (OR 7.7, p = 0.01). Conclusions: The FCGR3B NA1/NA1 genotype is associated with hypersensitivity reactions to adalimumab.

KW - Adalimumab

KW - Injection site reaction

KW - Polymorphism

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84995655502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995655502&partnerID=8YFLogxK

U2 - 10.1080/14397595.2016.1254709

DO - 10.1080/14397595.2016.1254709

M3 - Article

SP - 1

EP - 4

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

ER -